

CONFIDENTIAL, contact the Imaging Platform to collaborate on the findings herein



What groups of morphological features are distinguishing in the cluster relative to the untreated samples? (maximum of absolute m-score for the features belonging to the same category; m-score defined as median of a



Correlation

between

compound

the gene

scored

against the

gene using

L1000

profiling

correlation of the

compound signature

(95th DMSO

replicate correlation

is 0.52)

Chemical

structure

Mito

ER

available); blue/red colored

box means the matching

compound is

positively/negatively

correlated with the cluster

Which individual morphological features are distinguishing in the gene relative to the untreated samples? Blue/Red means the feature has a positive/negative z-score. Size is proportional to the z-score value.

Distinguishing individual features for the compound relative to Number of PubChem assays in which

the compound was tested; assays in

which the compound was active are


itemized

untreated samples. Black means a mismatch; i.e. active (= high

z-score in magnitude) in the compound, and either inactive (=

small z-score in magnitude) or oppositely active in the gene






Common distinguishing feature categories in the compound and


the gene relative to the untreated samples

How similar is the compound signature to the genes in this

experiment? (Yellow and red lines correspond to top/bottom

1st and 5th percentile DMSO correlation to all the genes)





- Total number of assays tested in: 667. Active in the following assays:
- Primary cell-based high throughput screening assay to measure STAT3 inhibition (AID 862)
 Primary cell-based high throughput screening assay to measure STAT1 activation (AID 932)
 Leishmania major promastigote HTS (AID 1063)
- Confirmation cell-based high throughput screening assay to measure STAT1 activation (AID 1262)
- Primary screen for compounds that activate Alzheimer's amyloid precursor (AID 1276)
- qHTS Assay for Enhancers of SMN2 Splice Variant Expression (AID 1458)
- Cycloheximide Counterscreen for Small Molecule Inhibitors of Shiga Toxin (AID 2314)
 A qHTS for Small Molecule Inhibitors of Shiga
- qHTS for inhibitors of ROR gamma transcriptional activity (AID 2551)
- qHTS Assay for Rab9 Promoter Activators (AID 485297)
- qHTS screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1 (AID 504466)
- qHTS profiling assay for firefly luciferase inhibitor/activator using purified enzyme and Km concentrations of substrates (counterscreen for
- concentrations of substrates (counterscreen for miR-21 project) (AID 588342)

 uHTS identification of Caspase-8 TRAIL sensi-
- tizers in a luminesence assay (AID 624354)
 Single concentration confirmation of Caspase-8 TRAIL sensitizer hits in a luminesence panel assay (AID 651596)
- Luminescence-based cell-based primary high throughput screening assay for inhibitors of the orphan nuclear receptor subfamily 0, group B, member 1 (DAX1; NR0B1): repression of SF-
- 1 (NR5A1) activated StAR promoter by full-length DAX-1 (AID 652010)
 Luminescence-based cell-based primary high throughput screening assay to identify activators of the DAF-12 from the parasite H. con-
- tortus (hcDAF-12) (AID 652067)

 Luminescence-based cell-based primary high throughput screening assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12). (AID 687014)
- Luminescence-based cell-based high throughput confirmation assay to identify agonists of the DAF-12 from the parasite H. contortus (hcDAF-12) (AID 743032)
- Luminescence-based cell-based high throughput confirmation assay to identify agonists of the DAF-12 from the parasite H. glycines (hgDAF-12). (AID 743050)